{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:59:58Z","timestamp":1769525998773,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["G059713N"],"award-info":[{"award-number":["G059713N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["G079614N"],"award-info":[{"award-number":["G079614N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UA","award":["NOI\/DOCPRO"],"award-info":[{"award-number":["NOI\/DOCPRO"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jprot.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T05:01:00Z","timestamp":1518498060000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-3583","authenticated-orcid":false,"given":"Martin","family":"Dom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Vanden Berghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xaveer","family":"Van Ostade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2018.02.013_bb0005","doi-asserted-by":"crossref","first-page":"120066","DOI":"10.1098\/rsob.120066","article-title":"Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?","volume":"2","author":"Borst","year":"2012","journal-title":"Open Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drup.2016.07.001","article-title":"Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics","volume":"28","author":"Wijdeven","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jprot.2018.02.013_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"de Mel","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jprot.2018.02.013_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ph9020033","article-title":"Tumor heterogeneity, single-cell sequencing, and drug resistance","volume":"9","author":"Schmidt","year":"2016","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jprot.2018.02.013_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jprot.2018.02.013_bb0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jprot.2018.02.013_bb0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/ijms17030290","article-title":"Withaferin-A\u2014A natural anticancer agent with pleitropic mechanisms of action","volume":"17","author":"Lee","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jprot.2018.02.013_bb0040","article-title":"Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells","volume":"9","author":"Szarc Vel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2007.04.010","article-title":"The tumor inhibitor and antiangiogenic agent Withaferin A targets the intermediate filament protein vimentin","volume":"14","author":"Bargagna-Mohan","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2193-9616-1-11","article-title":"Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A","volume":"1","author":"Saha","year":"2013","journal-title":"Silico Pharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0055","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/MCB.00895-15","article-title":"A novel allosteric mechanism of NF-\u03baB dimerization and DNA binding targeted by an anti-inflammatory drug","volume":"36","author":"Ashkenazi","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2014.08.004","article-title":"Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKK b","author":"Heyninck","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0065","series-title":"Antiproliferation Potential of Withaferin A on Human Osteosarcoma Cells via the Inhibition of G2\/M Checkpoint Proteins","first-page":"323","author":"Lv","year":"2015"},{"key":"10.1016\/j.jprot.2018.02.013_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1476-4598-9-99","article-title":"Differential chemosensitization of P-glycoprotein overexpressing K562\/Adr cells by withaferin A and Siamois polyphenols","volume":"9","author":"Suttana","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jprot.2018.02.013_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.steroids.2013.10.008","article-title":"Epoxide group relationship with cytotoxicity in withanolide derivatives from Withania somnifera","volume":"79","author":"Joshi","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.jprot.2018.02.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010105","article-title":"Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies","volume":"5","author":"Lahat","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio755","article-title":"Actin microfilament aggregation induced by withaferin A is mediated by annexin II","volume":"2","author":"Falsey","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0090","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1515\/hsz-2012-0184","article-title":"Withaferin A binds covalently to the N-terminal domain of annexin A2","volume":"393","author":"Ozorowski","year":"2012","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jprot.2018.02.013_bb0095","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1074\/jbc.M113.496844","article-title":"Growth arrest by the antitumor steroidal lactone withaferin a in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of \u03b2-tubulin","volume":"289","author":"Antony","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2018.02.013_bb0100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10495-007-0129-x","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine","volume":"12","author":"Malik","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.jprot.2018.02.013_bb0105","series-title":"Withaferin A Induces Apoptosis Hum. Melanoma Cells Through Gener. React. Oxyg. Species Down-Regulation Bcl-2","first-page":"1014","article-title":"Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2","volume":"16","author":"Mayola","year":"2011"},{"key":"10.1016\/j.jprot.2018.02.013_bb0110","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.yexcr.2013.08.026","article-title":"Production of reactive oxygen species by Withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K\/Akt, p38, and JNK pathways in rabbit articular chondrocytes","volume":"319","author":"Yu","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/0008-5472.CAN-06-2430","article-title":"Par-4-dependent apoptosis by the dietary compound Withaferin A in prostate cancer cells","volume":"67","author":"Srinivasan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0120","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/mc.22328","article-title":"Par-4 dependent modulation of cellular?? Catenin by medicinal plant natural product derivative 3-azido Withaferin A","volume":"55","author":"Amin","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.jprot.2018.02.013_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044039","article-title":"A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4","volume":"7","author":"Rah","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d","volume":"71","author":"Yang","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050547","article-title":"Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance","volume":"7","author":"Khan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0140","article-title":"Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-\u03ba B signaling","author":"Jackson","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/BCI.S18863","article-title":"Withaferin A inhibits STAT3 and induces tumor cell death in neuroblastoma and multiple myeloma","volume":"7","author":"Yco","year":"2014","journal-title":"Biochem. Insights."},{"key":"10.1016\/j.jprot.2018.02.013_bb0150","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jnci\/djt153","article-title":"Metabolic alterations in mammary cancer prevention by Withaferin A in a clinically relevant mouse model","volume":"105","author":"Hahm","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jprot.2018.02.013_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-013-9531-1","article-title":"Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone","volume":"16","author":"Vyas","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.jprot.2018.02.013_bb0160","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"ASH 50th anniversary review","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jprot.2018.02.013_bb0165","article-title":"Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim\/Bcl-2 complexes to activate Bax and Bak","volume":"16","author":"Melarangi","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jprot.2018.02.013_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-016-2216-2","article-title":"Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity","volume":"142","author":"Vaiou","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0175","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11059","article-title":"Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy","volume":"7","author":"Dytfeld","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jprot.2018.02.013_bb0180","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.4161\/cc.7.20.6832","article-title":"Simultaneous inhibition of the constitutively activated nuclear factor \u03baB and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells","volume":"7","author":"Malara","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jprot.2018.02.013_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106488","article-title":"Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid","volume":"9","author":"Van Raemdonck","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0190","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nmeth785","article-title":"Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations","volume":"2","author":"Elias","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jprot.2018.02.013_bb0195","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/pr070492f","article-title":"Nonlinear fitting method for determining local false discovery rates from decoy database searches","volume":"7","author":"Tang","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0200","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","article-title":"2016 update of the PRIDE database and its related tools","volume":"44","author":"Vizcaino","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bcp.2016.03.026","article-title":"Withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1\/Nrf2 pathway","volume":"109","author":"Heyninck","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.steroids.2007.10.006","article-title":"Selective reactivity of 2-mercaptoethanol with 5??,6??-epoxide in steroids from Withania somnifera","volume":"73","author":"Misra","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.jprot.2018.02.013_bb0215","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1016\/j.jprot.2012.03.003","article-title":"On-bead tryptic proteolysis: an attractive procedure for LC-MS\/MS analysis of the Drosophila caspase 8 protein complex during immune response against bacteria","volume":"75","author":"Fukuyama","year":"2012","journal-title":"J. Proteome"},{"key":"10.1016\/j.jprot.2018.02.013_bb0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.200805092","article-title":"Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes","volume":"183","author":"Trinkle-Mulcahy","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.pharmtox.010909.105600","article-title":"Mechanisms of cell protection by heme oxygenase-1","volume":"50","author":"Gozzelino","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0230","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1158\/0008-5472.CAN-06-3089","article-title":"Proteomic analysis of Waldenstrom macroglobulinemia","volume":"67","author":"Hatjiharissi","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0235","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00345-010-0575-x","article-title":"The role of annexins I, II and IV in tumor development, progression and metastasis of human penile squamous cell carcinomas","volume":"29","author":"Protzel","year":"2011","journal-title":"World J. Urol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053263","article-title":"Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib","volume":"8","author":"Gelman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0245","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from \u201cIndian winter cherry\u201d","volume":"71","author":"Yang","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jep.2015.09.024","article-title":"Identification and quantitative analysis of cellular proteins affected by treatment with Withaferin A using a SILAC-based proteomics approach","volume":"175","author":"Narayan","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0255","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3892\/mmr.2016.5666","article-title":"Proteomic analysis of selective cytotoxic anticancer properties of flavonoids isolated from Citrus platymamma on A549 human lung cancer cells","volume":"14","author":"Nagappan","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jprot.2018.02.013_bb0260","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"G.K.S.& M.P.-P","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jprot.2018.02.013_bb0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1083\/jcb.200805092","article-title":"Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes","volume":"183","author":"Trinkle-Mulcahy","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0270","first-page":"14","article-title":"Withaferin a inhibits the proteasome activity in mesothelioma in vitro and in vivo","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0275","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbamcr.2008.01.003","article-title":"Building and operating an antibody factory: redox control during B to plasma cell terminal differentiation","volume":"1783","author":"Masciarelli","year":"2008","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.jprot.2018.02.013_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2013.00109","article-title":"The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis","volume":"4","author":"White-Gilbertson","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.jprot.2018.02.013_bb0285","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","article-title":"Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97","volume":"24","author":"Sha","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0290","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1074\/jbc.M111.277145","article-title":"Nrf2-dependent induction of proteasome and Pa28\u03b1\u03b2 regulator are required for adaptation to oxidative stress","volume":"287","author":"Pickering","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2018.02.013_bb0295","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1128\/MCB.23.23.8786-8794.2003","article-title":"Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway","volume":"23","author":"Kwak","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","article-title":"Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells","volume":"38","author":"Radhakrishnan","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jprot.2018.02.013_bb0305","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2018.02.013_bb0310","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.014035","article-title":"Identification of autophagosome-associated proteins and regulators by quantitative proteomic analysis and genetic screens","volume":"11","author":"Dengjel","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jprot.2018.02.013_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0134137","article-title":"Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells","volume":"10","author":"Nishikawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2018.02.013_bb0320","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2174\/15680096113139990039","article-title":"Autophagy fails to alter Withaferin A-mediated lethality in human breast cancer cells","volume":"13","author":"Hahm","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jprot.2018.02.013_bb0325","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/15548627.2016.1191722","article-title":"Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells","volume":"12","author":"Li","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.jprot.2018.02.013_bb0330","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jprot.2018.02.013_bb0335","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/emboj.2009.405","article-title":"HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy","volume":"29","author":"Lee","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.jprot.2018.02.013_bb0340","series-title":"Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma","author":"Vogl","year":"2017"},{"key":"10.1016\/j.jprot.2018.02.013_bb0345","doi-asserted-by":"crossref","first-page":"59727","DOI":"10.18632\/oncotarget.10847","article-title":"Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation","volume":"5","author":"Shah","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jprot.2018.02.013_bb0350","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1146\/annurev-biochem-060809-095203","article-title":"Regulation of HSF1 function in the heat stress response: implications in aging and disease","volume":"80","author":"Anckar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jprot.2018.02.013_bb0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12164","article-title":"The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma","volume":"160","author":"Heimberger","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jprot.2018.02.013_bb0360","series-title":"HSF1 Stress Response Pathway Regulates Autophagy Receptor SQSTM1\/p62-Associated Proteostasis","first-page":"133","volume":"8627","author":"Watanabe","year":"2017"},{"key":"10.1016\/j.jprot.2018.02.013_bb0365","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.freeradbiomed.2014.03.025","article-title":"Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics","volume":"71","author":"Levonen","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jprot.2018.02.013_bb0370","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jprot.2018.02.013_bb0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e1n","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jprot.2018.02.013_bb0380","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CAD.0b013e3282f24031","article-title":"Antioxidants block proteasome inhibitor function in endometrial carcinoma cells","volume":"19","author":"Llobet","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jprot.2018.02.013_bb0385","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.408","article-title":"JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress","volume":"5","author":"Kostecka","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jprot.2018.02.013_bb0390","first-page":"1","article-title":"Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical Withaferin A","author":"Chirumamilla","year":"2017","journal-title":"Proc. Nutr. Soc."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391918300617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391918300617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T02:45:32Z","timestamp":1603853132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391918300617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":78,"alternative-id":["S1874391918300617"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2018.02.013","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}